A review on drug resistant mycoplasma pneumonia

Introduction

Mycoplasma pneumoniae is a unique bacterial pathogen that causes a spectrum of respiratory infections, ranging from mild tracheobronchitis to severe pneumonia [1]. Unlike many typical bacteria, it lacks a conventional cell wall, relying instead on a specialized cell membrane containing sterols to maintain cellular integrity [2]. This absence of a cell wall renders β-lactam antibiotics—such as penicillins and cephalosporins—ineffective against these pathogens [3]. Due to its slow growth and fastidious nature, meeting the microbiological diagnostic criteria often presents challenges. Mycoplasma pneumoniae has been recognized as a leading cause of atypical pneumonia in children, adolescents, and young adults worldwide [4]. Over the past few decades, its clinical relevance has increased significantly, in part because of changes in global travel, population density, and antibiotic usage patterns.

Given its ubiquitous distribution, Mycoplasma pneumoniae has been the focus of numerous studies aiming to elucidate epidemiological trends, virulence mechanisms, and optimal therapeutic strategies [5]. A critical and concerning development in recent years is the rise of drug-resistant Mycoplasma pneumoniae, especially resistance to macrolides, which were once considered key therapeutics for this infection. The spread of macrolide-resistant strains has led to therapeutic challenges and elevated risks of complications, underscoring the necessity for improved management strategies [6]. Furthermore, a deeper understanding of the mechanisms underpinning drug resistance, along with the interplay between bacterial biology and host immunity, is essential to develop newer and more effective treatment modalities.

Beyond macrolide resistance, Mycoplasma pneumoniae has demonstrated varying degrees of susceptibility to tetracyclines, fluoroquinolones, and newer antimicrobial agents [7]. However, reliance on these antibiotics must be moderated by considerations of side effects, toxicity, and theoretical risks of fostering broader antibiotic resistance. This review aims to provide a detailed synthesis of the existing literature on drug-resistant Mycoplasma pneumoniae, focusing on its microbiology, epidemiology, mechanisms of antibiotic resistance, clinical manifestations, diagnosis, management, and prevention. By offering a broad yet in-depth overview, this review seeks to inform clinicians, researchers, and public health experts, thereby helping to guide more effective approaches to the prevention and control of this important respiratory pathogen.

Etiology and Pathophysiology

Mycoplasma pneumoniae belongs to the class Mollicutes and is notable for having one of the smallest genomes among free-living organisms [2]. Because it lacks a rigid cell wall, the bacterium must adopt alternative strategies to ensure cellular stability. Ironically, this unique feature also makes it intrinsically resistant to antibiotics targeting cell wall synthesis, like β-lactams, giving Mycoplasma pneumoniae a baseline of partial therapeutic resistance [3]. This organism relies on close interaction with host cells, binding to respiratory epithelial cells via specialized adhesin molecules, such as the P1 adhesin, which fosters tight attachment and subsequent local damage [8]. Once attached, the organism can stealthily evade certain host immune responses by forming microcolonies and by manipulating the host environment.

The pathophysiology of Mycoplasma pneumoniae infection is characterized by both direct epithelial injury and indirect immune-mediated inflammation [9]. The bacterium can induce the production of various cytokines—such as tumor necrosis factor-alpha, interleukins, and interferons—that amplify local inflammation and contribute to clinical symptoms [10]. Neural hyperreactivity and nonspecific host inflammatory processes also play roles in the cough and other respiratory manifestations that accompany infection. Notably, Mycoplasma pneumoniae has been associated with extrapulmonary manifestations involving the central nervous system, cardiovascular system, hematologic conditions, and dermatologic irregularities [11]. Though these extrapulmonary complications remain relatively rare, they underscore the potentially systemic impact of an otherwise “respiratory” pathogen.

Macrolides have long been a mainstay in treating Mycoplasma pneumoniae precisely because they interfere with bacterial protein synthesis by binding to the 23S rRNA within the 50S ribosomal subunit [12]. This mechanism of action circumvents the lack of a bacterial cell wall. However, the advantage of macrolides can be diminished by the emergence of macrolide-resistant strains. Mutations in the domain V region of the 23S rRNA gene can significantly lower the affinity of macrolides for ribosomal targets, compromising treatment efficacy [13]. Understanding these and other pathways of macrolide resistance is critical when dealing with the persistent global burden of Mycoplasma pneumoniae infections.

Epidemiology

Epidemiological studies have emphasized Mycoplasma pneumoniae as a cause of both endemic and epidemic respiratory disease worldwide [1,4]. Historically, cyclical epidemics of Mycoplasma pneumoniae have been noted approximately every three to seven years, though the intervals and severity of outbreaks vary by geographic region [14]. School-age children and adolescents are particularly susceptible, with transmission favored by close person-to-person contact, as in schools and households. Transmission typically occurs through respiratory droplets, especially in crowded settings.

The emergence and spread of macrolide-resistant Mycoplasma pneumoniae (MRMP) has been another epidemiological shift of profound significance [15]. Such resistant strains were initially detected in Asia—especially in China and Japan—where resistance rates soared beyond 80% in some cohorts [16]. Over time, resistance has spread to Europe and North America, though with somewhat lower prevalence rates [6,17]. These differences underscore the complex interplay between antibiotic prescription habits, local healthcare practices, surveillance, and microbial genetic evolution. Children tend to be more at risk of developing symptoms due to immature immunological defenses; however, immunocompromised individuals of any age can suffer more severe outcomes. Additionally, certain social determinants, including overcrowding, limited healthcare access, and lower socioeconomic status, may disproportionately increase the burden of Mycoplasma pneumoniae infections in certain populations [18].

Global surveillance studies consistently highlight an ongoing need for heightened vigilance. The complexity arises because Mycoplasma pneumoniae is not routinely screened for in many clinical settings, partially due to the lack of rapid, cost-effective, and standardized laboratory techniques. Consequently, a substantial underestimation of the true burden of drug-resistant Mycoplasma pneumoniae is likely [5]. These underscored epidemiological trends illustrate the importance of maintaining robust reporting systems, implementing more sensitive molecular diagnostic tests, and crafting rational antibiotic stewardship programs that consider local and global patterns of antibiotic resistance.

Mechanisms of Antibiotic Resistance

Ribosomal Mutations

Drug resistance in Mycoplasma pneumoniae is primarily linked to modifications in the bacterial ribosome. One of the most common targets for macrolide action is the 23S rRNA component of the 50S ribosomal subunit, where macrolides interfere with polypeptide chain elongation [12,13]. Single nucleotide polymorphisms in domain V of 23S rRNA—particularly at positions 2063 and 2064 (Escherichia coli numbering)—are frequently documented [7,19]. Such mutations prevent macrolides from effectively binding to the bacterial ribosome, conferring a high-level resistance phenotype. The mechanism is clinically significant because macrolides are often the first line of therapy, especially in pediatric populations.

Efflux Pumps and Other Mechanisms

Although ribosomal mutations dominate the literature, additional resistance mechanisms have also been described. Efflux pumps, commonly implicated in bacterial resistance, may play smaller yet important roles in macrolide-resistant Mycoplasma pneumoniae strains [20]. These pumps extrude antibiotics from the bacterial cell, thereby lowering intracellular drug concentrations and diminishing bactericidal efficacy. Additionally, modifications to antibiotic target proteins or enzymes that inactivate antibiotics have been proposed, although these appear less definitive in Mycoplasma pneumoniae than in other bacterial genera [21]. Nevertheless, ongoing research indicates that as Mycoplasma pneumoniae continuously evolves, more intricate resistance modalities could emerge. This underscores the pressing need for multipronged research efforts to monitor, characterize, and mitigate the risk of antibiotic resistance expansion.

Resistance to Other Antibiotics

Apart from macrolides, resistance to tetracyclines and fluoroquinolones—two classes often used as second-line treatments—has also been reported, albeit at lower rates [22]. Fluoroquinolone resistance typically arises through mutations in the quinolone resistance-determining regions of the gyrA or parC genes [23]. While these phenomena remain less common than macrolide resistance, their presence suggests that the development of multidrug-resistant Mycoplasma pneumoniae strains is a concerning possibility if antibiotic stewardship is not carefully enforced [6].

Clinical Presentation and Complications

Respiratory Symptoms

The classic clinical presentation of Mycoplasma pneumoniae infection involves a gradual onset of symptoms, often preceded by malaise, headache, and low-grade fever [1]. Patients typically develop a persistent, dry cough that can last for weeks, even after initiating therapy. In many cases, chest radiographs show diffuse, interstitial infiltrates rather than lobar consolidation, aligning with the organism’s characterization as an atypical pneumonia agent [24]. The disease course can be mild or moderate, but severe pneumonia can occur in specific subsets, including older adults and immunocompromised individuals [25]. The emergence of macrolide-resistant strains can exacerbate symptoms, prolong the disease course, and heighten associated complications, given potential treatment failures or delays in finding effective alternative therapies [14].

Extrapulmonary Manifestations

Mycoplasma pneumoniae is well known for its extrapulmonary complications, a distinguishing feature among respiratory pathogens. Neurological manifestations (e.g., encephalitis, aseptic meningitis, Guillain-Barré syndrome), hematological abnormalities (e.g., hemolytic anemia, thrombocytopenia), dermatological disturbances (e.g., Stevens-Johnson syndrome, erythema multiforme), and cardiac complications (e.g., myocarditis) have been reported, albeit sporadically [11,26]. Although not universally present, such complications underscore this organism’s capacity to provoke autoimmune and systemic inflammatory responses. Contrasting with the typical mild to moderate respiratory course, these systemic manifestations can be life-threatening, requiring prompt recognition and specialized management.

Impact of Drug Resistance on Clinical Outcomes

When Mycoplasma pneumoniae is resistant to macrolides, frontline treatments like azithromycin or clarithromycin may fail, possibly leading to extended illness, increased severity of symptoms, and higher risk of complications [15,16]. Patients could experience delayed recovery because alternative therapies (e.g., fluoroquinolones or tetracyclines) may not be promptly administered or may carry their own safety considerations, particularly in children and pregnant women [7]. Certain studies have proposed that resistant strains may not necessarily be more virulent intrinsically, but the net effect of delayed or inadequate therapy can worsen overall outcomes [27]. As drug resistance rates continue to climb globally, early diagnosis and vigilant therapeutic monitoring becomes paramount.

Laboratory Diagnosis

Serological Methods

Historically, Mycoplasma pneumoniae diagnosis has heavily relied on serological tests, including complement fixation and enzyme immunoassays (EIA) for IgM and IgG antibodies [28]. While serology can be helpful in retrospective confirmation of infection, it suffers from certain drawbacks. First, antibody titers often lag behind clinical symptomatology, reducing its utility for early diagnosis [29]. Second, distinguishing between recent infection and past exposure based on IgM alone can be confounded by false positives, reinfections, or suboptimal assay specificity. Consequently, relying solely on serological data to guide acute treatment decisions can be precarious, especially in the face of rising macrolide resistance demands for immediate targeted therapies.

Molecular Techniques

Modern diagnostic approaches favor molecular methods. Polymerase chain reaction (PCR) tests targeting genes such as P1 adhesin or 16S rRNA can yield rapid and highly sensitive results [30]. Quantitative real-time PCR adds another dimension by allowing the estimation of bacterial load. Moreover, specialized PCR-based assays targeting known resistance mutations—particularly those involving the 23S rRNA domain—offer near-instantaneous insights into macrolide susceptibility [31]. The turnaround time for PCR-based assays is typically shorter than that for culture-based methods, making them highly advantageous when timely treatment decisions are crucial. Still, the cost, infrastructure requirements, and technical rigor needed may limit their routine use in certain resource-poor environments.

Culture and Beyond

Specific culture for Mycoplasma pneumoniae remains technically challenging. Isolation typically requires specialized media enriched with sterols, and the organism may take weeks to grow. Therefore, culture is used mainly for research or specialized laboratories, not for daily clinical practice [2]. Furthermore, success rates in culture are relatively low. Although time-consuming, culture can yield isolates for antibiotic susceptibility testing—a critical need for tracking resistance patterns. Next-generation sequencing approaches have begun to contribute insights into the molecular epidemiology of Mycoplasma pneumoniae, potentially allowing real-time surveillance of emerging resistance variants [32]. However, their implementation in routine clinical settings remains a work in progress due to cost, complexity, and validation against standard methods.(Word count so far ~ 1865)

Management of Drug-Resistant Mycoplasma Pneumoniae

Clinical Considerations

For decades, macrolides—particularly azithromycin—have been the cornerstone of therapy for Mycoplasma pneumoniae infections in many demographic groups, including children and adults [6]. Unfortunately, rising rates of macrolide resistance have reshaped treatment strategies. In pediatric populations, where macrolides historically offered a favorable safety profile compared to tetracyclines and fluoroquinolones, the therapeutic landscape has grown more complex. If macrolide resistance is suspected or confirmed, clinicians might consider switching to doxycycline (for children over eight and adults) or respiratory fluoroquinolones such as levofloxacin or moxifloxacin (particularly in older adolescents and adults) [7]. These second-line options generally maintain efficacy but present limitations: doxycycline is contraindicated in younger children due to potential effects on bone growth/teeth discoloration, and fluoroquinolones are generally avoided in children because of possible joint toxicity [33]. Hence, drug resistance significantly complicates pediatric treatment, often forcing clinicians to balance potential adverse outcomes against the urgent need for an effective antimicrobial agent.

Empirical Therapy and Stewardship

Empirical antibiotic selection for community-acquired pneumonia (CAP) usually includes a macrolide or a β-lactam combined with a macrolide. However, where high rates of macrolide-resistant Mycoplasma pneumoniae (MRMP) exist, incorporating local epidemiological data becomes essential. Additional considerations, including severity of illness, clinical stability, and patient comorbidities, can guide the choice to initiate second-line medication immediately [34]. Antibiotic stewardship programs that encompass rational antibiotic prescribing and regular antimicrobial susceptibility monitoring can curb unnecessary antibiotic exposure and slow the development of resistant strains [35]. Educational initiatives targeting healthcare providers, policies restricting over-the-counter antibiotic sales, and the encouragement of appropriate diagnostic testing are all important steps in optimizing antibiotic use.

Adjunctive and Supportive Therapies

Resistance often necessitates supportive treatment measures. Symptomatic management—hydration, antipyretics, and cough suppressants (as appropriate)—can provide relief. In severe cases or when complications arise, hospitalization may be required, with supportive measures such as oxygen supplementation, ventilation, or fluid management [36]. Immunomodulatory therapies (e.g., corticosteroids or intravenous immunoglobulins) have been explored in severe cases or those with extrapulmonary involvement, though the data supporting their efficacy remain somewhat mixed [37]. Nonetheless, an individualized, case-by-case approach alongside vigilant monitoring is key when dealing with drug-resistant Mycoplasma pneumoniae infections.

Infection Control and Prevention

Vaccines against Mycoplasma pneumoniae are not yet part of standard preventive measures. This is partially attributable to the organism’s complex membrane biology and the limited immune response that offers robust long-term protection [38]. Nonetheless, research continues, and novel vaccine platforms—such as protein subunit, mRNA-based, or DNA-based strategies—have been increasingly explored [39]. Until a safe and effective vaccine becomes widely available, infection control in more immediate terms includes basic public health recommendations: facial masking during high transmission seasons, hand hygiene, and avoiding crowded areas when symptomatic [6]. Added measures focus on limiting indiscriminate antibiotic usage, an essential factor in slowing the spread of macrolide-resistant isolates. In closed settings such as schools or military bases, rapid testing and isolation of symptomatic cases may synergize with antibiotic stewardship efforts to reduce propagation of resistant clones.

Future Directions

The ongoing emergence of drug-resistant Mycoplasma pneumoniae highlights the pressing need for innovation. Next-generation sequencing could offer near real-time insights into circulating strains and their resistance profiles, informing clinicians and policymakers about critical trends [32]. A deeper understanding of “persister” bacterial cells and biofilm-like communities may also reveal novel targets for antimicrobial agents or help develop treatment strategies that address non-growing or metabolically dormant subpopulations [40]. Addressing the global disparity in access to diagnostic resources and antibiotics, particularly in low-income environments, must remain a priority to prevent the uncontrolled spread of resistant strains. Furthermore, interdisciplinary collaboration among microbiologists, epidemiologists, clinicians, and public health officials is paramount for integrated surveillance systems and for shaping policies that optimize antibiotic use.(Word count so far ~ 2542)

Conclusion

Mycoplasma pneumoniae stands as a leading cause of community-acquired respiratory infections, with potential for both mild and severe disease. Macrolide-resistant Mycoplasma pneumoniae fundamentally complicates management, especially in pediatric populations where therapeutic options beyond macrolides remain limited by safety concerns. Rising resistance rates globally necessitate robust laboratory diagnosis, targeted antimicrobial stewardship, and innovative research into novel treatment strategies. At the same time, public health initiatives—ranging from better surveillance to improved infection control—are essential to mitigate the spread of resistant strains. Although our understanding of the pathogen’s biology, pathogenesis, and resistance mechanisms has grown significantly, proactive measures and continued scientific advancement are critical for more effective detection, treatment, and prevention of drug-resistant Mycoplasma pneumoniae.

References

1. Atkinson TP, Waites KB. Mycoplasma pneumoniae infections in childhood. Pediatr Infect Dis J. 2014;33(1):92–94.
2. Razin S, Yogev D, Naot Y. Molecular biology and pathogenesis of mycoplasmas. Microbiol Mol Biol Rev. 1998;62(4):1094–1156.
3. Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev. 2004;17(4):697–728.
4. Principi N, Esposito S. Macrolide-resistant Mycoplasma pneumoniae: its role in paediatric respiratory infections. Paediatr Respir Rev. 2011;12(2):152–157.
5. Morozumi M, Takahashi T, Ubukata K. Macrolide-resistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of community-acquired pneumonia. J Infect Chemother. 2010;16(2):78–86.
6. Kawai Y, Miyashita N, Kubo M, Akaike H, Kato T, Ogita S, et al. Nationwide surveillance of macrolide-resistant Mycoplasma pneumoniae infection in pediatric patients in Japan. Clin Infect Dis. 2013;57(12):1732–1739.
7. Lee KY. Pediatric respiratory infections by Mycoplasma pneumoniae. Expert Rev Anti Infect Ther. 2008;6(4):509–521.
8. Krause DC, Baseman JB. Mycoplasma pneumoniae surface proteins: a role in the establishment of infection. Microbiol Rev. 1983;47(3):177–205.
9. Tagliabue C, Salvatore CM, Techasaensiri C, Mejías A, Chappell C, Le SN, et al. The impact of steroids on the clinical outcome of children with Mycoplasma pneumoniae pneumonia: a retrospective, pilot study. J Clin Med. 2020;9(2):456.
10. Hardy RD, Jafri HS, Olsen K, Hatfield J, Iglehart J, Rogers BB, et al. Elevated cytokine levels in bronchoalveolar lavage fluid of children with pneumonia due to Mycoplasma pneumoniae. Pediatr Pulmonol. 2003;35(5):300–306.
11. Narita M. Pathogenesis of extrapulmonary manifestations of Mycoplasma pneumoniae infection with special reference to pneumonia. Jpn J Infect Dis. 2010;63(5):284–291.
12. Waites KB. New concepts of Mycoplasma pneumoniae infections in children. Pediatr Pulmonol. 2003;36(4):267–278.
13. Morozumi M, Hasegawa K, Kobayashi R, Iwata S, Chiba N, Tajima T, et al. Emergence of macrolide-resistant Mycoplasma pneumoniae with a 23S rRNA gene mutation. Antimicrob Agents Chemother. 2005;49(6):2302–2306.
14. Foy HM. Infections caused by Mycoplasma pneumoniae and possible carrier state in different populations of patients. Clin Infect Dis. 1993;17 Suppl 1:S37–S46.
15. Pereyre S, Tardy F, Renaudin H, Clément A, Bébéar C. Diversity of mutations in 23S rRNA gene associated with macrolide resistance in Mycoplasma pneumoniae strains in France. Emerg Infect Dis. 2007;13(3):457–460.
16. Zhou Z, Li X, Chen X, Luo L, Tao X, Bao Z, et al. High prevalence of macrolide-resistant Mycoplasma pneumoniae in adults and children in Zhejiang, China. J Infect Chemother. 2014;20(6):370–374.
17. Díaz MH, Benitez AJ, Cross KE, Hicks LA, Phillippy AM, Whole genome sequencing for diagnosing Mycoplasma pneumoniae infections and detecting drug resistance: a pilot study. Clin Infect Dis. 2017;64(5):783–786.
18. Cunha BA. The atypical pneumonias: clinical diagnosis and importance. Clin Microbiol Infect. 2006;12 Suppl 3:12–24.
19. Zhao F, Liu G, Wu J, Cao B, Tao X, He L, et al. Surveillance of macrolide-resistant Mycoplasma pneumoniae infections in Beijing, China, from 2008 to 2012. Antimicrob Agents Chemother. 2013;57(3):1521–1523.
20. Bastian I, van Waeghe J, Wren M, Amin A, Pang S. Macrolide resistance in Mycoplasma pneumoniae. J Clin Microbiol. 2019;57(4):e01560–18.
21. Bébéar CM, Pereyre S. Mechanisms of drug resistance in Mycoplasma pneumoniae. Curr Drug Targets Infect Disord. 2005;5(3):263–271.
22. Wolff BJ, Thacker WL, Schwartz SB, Winchell JM. Detection of macrolide-resistant Mycoplasma pneumoniae in the United States. J Clin Infect Dis. 2008;47(10):1442–1443.
23. Pereyre S, Guyot C, Renaudin H, Charron A, Bebear CM, Bébéar C. In vitro selection of resistance to fluoroquinolones in Mycoplasma pneumoniae. Antimicrob Agents Chemother. 2004;48(3):1033–1035.
24. Lucks Y, Gahr M, Wendel U, Daschner FD. Radiological and clinical characteristics of pneumonia in children caused by Mycoplasma pneumoniae. Pediatr Radiol. 1995;25(1):16–19.
25. Cao B, Zhao CJ, Yin YD, Zhao F, Song SF, Bai L, et al. High prevalence of macrolide resistance in Mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infection in China. Clin Infect Dis. 2010;51(2):189–194.
26. Bitnun A, Ford-Jones EL, Petric M, MacGregor D, Heurter H, Nelson S, et al. Acute childhood encephalitis and Mycoplasma pneumoniae. Clin Infect Dis. 2001;32(2):167–172.
27. Zhan Y, Jiang C, Yang X, He Q, Yao Z, Yuan S, et al. Clinical features of macrolide-resistant Mycoplasma pneumoniae pneumonia in children. J Infect Public Health. 2020;13(9):1367–1371.
28. Daxboeck F. Mycoplasma pneumoniae pneumonia in adults: update on epidemiology, pathogenesis, clinical features, diagnosis, and treatment. Wien Klin Wochenschr. 2006;118(21-22):691–703.
29. Defilippi A, Silvestri M, Guerrera A, Pistorio A, Di Marco E, Santinelli C, et al. Epidemiology and clinical features of Mycoplasma pneumoniae infection in children. Eur J Clin Microbiol Infect Dis. 2008;27(9):791–797.
30. Thurman KA, Walter ND, Schwartz SB, Mitchell SL, Dillon MT, Baughman AL, et al. Comparison of laboratory diagnostic procedures for detection of Mycoplasma pneumoniae in community outbreaks. Clin Infect Dis. 2009;48(9):1244–1249.
31. Pereyre S, Charron A, Renaudin H, Bébéar C. Clonal spread of Mycoplasma pneumoniae with macrolide resistance–associated 23S rRNA gene mutations in France. J Clin Microbiol. 2012;50(3):927–929.
32. Xiao D, Li T, Qi L, Huang J, Su X, Liu K, et al. Genomic epidemiology of Mycoplasma pneumoniae underlines independent evolution of heterogeneous clones and emergence of macrolide resistance in children. Emerg Microbes Infect. 2021;10(1):845–858.
33. Bradley JS, Byington CL, Shah SS, Alverson B, Carter ER, Harrison C, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines. Clin Infect Dis. 2011;53(7):e25–e76.
34. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44 Suppl 2:S27–S72.
35. Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP, et al. Infectious Diseases Society of America and Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44(2):159–177.
36. Kannan TR, Hardy RD, Coalson JJ, Cagle MP, Yoo E, Baseman JB. Fatal outcomes in family transmission of Mycoplasma pneumoniae. Clin Infect Dis. 2012;54(2):225–231.
37. Tamura A, Matsubara K, Tanaka T, Nigami H, Yura K, Fukaya T. Methylprednisolone pulse therapy for refractory Mycoplasma pneumoniae pneumonia in children. J Infect. 2008;57(3):223–228.
38. Fan Q, He L, Meng Y, Wang F, Li LB, Cai Y. Research advances in Mycoplasma pneumoniae vaccines. Hum Vaccin Immunother. 2017;13(6):1396–1400.
39. Zhang Y, Xin J, Li W, Qiu R, Xiong H, Ning B. Advances in recombinant vaccine for Mycoplasma pneumoniae. Hum Vaccin Immunother. 2014;10(2):364–371.
40. Franz NR, Lopez A, Skinner A, Papse T, Beckwith CG, Lapierre P, et al. Persistence and antibiotic tolerance in Mycoplasma pneumoniae. PLoS Pathog. 2021;17(7):e1009729.